Prelude is developing PRT2527, which is designed to be a potent and selective CDK9 inhibitor. PRT2527 was shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses. PRT2527 has demonstrated high potency and kinase selectivity which may offer improved efficacy and safety compared to less selective CDK9 inhibitors. It is being evaluated in a Phase 1 dose escalation study in patients whose cancers are likely to be dependent on CDK9.
PRT2527 is designed to be a potent and selective CDK9 inhibitor.